Michael A. Curran, Ph.D.
Affiliations: | 2001 | Stanford University, Palo Alto, CA |
Area:
Molecular Biology, Microbiology Biology, ImmunologyGoogle:
"Michael Curran"Parents
Sign in to add mentorGarry P. Nolan | grad student | 2001 | Stanford | |
(Development and application of feline immunodeficiency virus vectors for gene therapy.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Reilley MJ, Morrow B, Ager CR, et al. (2019) TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Journal For Immunotherapy of Cancer. 7: 323 |
Ager CR, Zhang H, Wei Z, et al. (2019) Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorganic & Medicinal Chemistry Letters. 126640 |
Zamler D, Yen E, Shingu T, et al. (2019) IMMU-10. ESTABLISHING EFFECTIVE MODELS FOR IMMUNOTHERAPY IN GBM Neuro-Oncology. 21: vi121-vi121 |
Bartkowiak T, Singh S, Yang G, et al. (2015) Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proceedings of the National Academy of Sciences of the United States of America. 112: E5290-9 |
Bartkowiak T, Curran MA. (2015) 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Frontiers in Oncology. 5: 117 |
Callahan MK, Horak CE, Curran MA, et al. (2013) Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Journal of Clinical Oncology. 31: 3003-3003 |
Callahan MK, Horak CE, Curran MA, et al. (2013) Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab Journal For Immunotherapy of Cancer. 1 |
Mineharu Y, Muhammad AK, Yagiz K, et al. (2012) Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 9: 827-43 |
Jenq RR, Curran MA, Goldberg GL, et al. (2012) Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. Plos One. 7: e35222 |
Curran MA, Kim M, Montalvo W, et al. (2011) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Plos One. 6: e19499 |